OVERVIEW

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Meloxicam – Generic, Mobic®

DRUG CLASS

Nonsteroidal Antiinflammatory Drugs

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

View in own window

DRUG	CAS REGISTRY NUMBER	MOLECULAR FORMULA	STRUCTURE
Meloxicam	71125-38-7	C14-H13-N3-O4-S2

ANNOTATED BIBLIOGRAPHY

References updated: 30 July 2025

Abbreviations used: NSAID, nonsteroidal antiinflammatory drug.

• Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. The NSAIDS. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-41.

  (Review of hepatotoxicity of NSAIDs published in 1999; meloxicam is not discussed).
• Lewis JH, Stine JG. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd Edition. Amsterdam: Elsevier, 2013. pp. 370-402.

  (Textbook of hepatotoxicity published in 2013 mentions that meloxicam had yet to be associated with hepatic abnormalities).
• Grossner T, Smyth EM, Fitzgerald GA. Pharmacotherapy of inflammation, fever, pain and gout. In, Brunton LL, Hilal Dandan R, Knollman BC. Goodman & Gilman’s The pharmacological basis of therapeutics, 13th ed. New York: McGraw-Hill, 2018. pp. 685-709.

  (Textbook of pharmacology and therapeutics).
• Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroid drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990; 10: 322-8. [PubMed: 2281340]

  (Review of liver injury due to NSAIDs; meloxicam is not mentioned).
• Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 (Suppl 1): 68-77. [PubMed: 8630641]

  (Analysis of safety of 7.5 and 15 mg of meloxicam among 4175 patients in controlled trials in rheumatoid arthritis and osteoarthritis; ALT or AST elevations occurred in 5.9% at 7.5 mg, 7.4% at 15 mg, vs 6.3% with piroxicam, 16.1% with diclofenac and 9.5% with naproxen).
• Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum 1997; 26: 21-7. [PubMed: 9219316]

  (Safety analysis in over 4000 patients on meloxicam; fewer gastrointestinal complaints with meloxicam; similar data as in Distel [1996]: ALT levels >2 times ULN occurred in 2% of meloxicam vs 5% of diclofenac recipients; no mention of hepatitis or jaundice).
• Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity. Acta Gatroenterol Belg 1999; 62: 255-6. [PubMed: 10427794]

  (46 year old woman with rheumatoid arthritis developed anorexia 4 days after starting meloxicam, and despite stopping developed fatigue and jaundice 8 days later [bilirubin 10.4 mg/dL, ALT 2340 U/L, Alk P 520 U/L], resolving within 1 month of stopping; was ANA positive, but without rash, fever or eosinophilia: patient had tolerated piroxicam without difficulty).
• Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50: 35-42. [PMC free article: PMC2014964] [PubMed: 10886116]

  (Among 19,087 users of meloxicam common side effects were dyspepsia, abdominal pain, nausea, headache and rash; but only one patient had “idiosyncratic liver abnormalities”, but details not given).
• Gierer IM, Abdala O, Calderón C, Risoli E, Cravero A, Pinchuk L. [Meloxican-induced cholestasis] Acta Gastroenterol Latinoam 2000; 30: 511-4. Spanish. PMID: 11144948 [PubMed: 11144948]

  (75 year old woman developed pruritus after 2 weeks and jaundice after 5 weeks of meloxicam therapy and at 7 weeks had bilirubin 25 mg/dL, ALT 40 U/L, Alk P 559 U/L, biopsy showing intrahepatic cholestasis with slow, but complete resolution by 4 months).
• Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P, Meloxicam Osteoarthritis Investigators. Safety and efficacy of meloxicam in the treatment of osteoarthritis. A 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med 2000; 160: 2947-54. [PubMed: 11041902]

  (Among 774 patients enrolled at 61 centers in an industry supported randomized controlled trial of 3 doses of meloxicam vs placebo or diclofenac for 12 weeks, side effects were less with meloxicam than with diclofenac, but more than with placebo; no mention of ALT elevations or liver injury).
• Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, et al. Meloxicam Rheumatoid Arthritis Investigators. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29: 436-46. [PubMed: 11908554]

  (Among 894 patients with rheumatoid arthritis enrolled in an industry supported randomized clinical trial of 3 doses of meloxicam vs placebo or diclofenac for 12 weeks, ALT elevations were less common with meloxicam [6.9-8.9%] than with placebo [12.2%] and much less than with diclofenac [30%]).
• Fleischmann R, Iqbal I, Stobodin G. Meloxicam. Expert Opin Pharamcother 2002; 3: 1501-12. [PubMed: 12387696]

  (Overview of this Cox-2 preferential NSAID showing similar therapeutic activity to piroxicam and diclofenac with less gastrointestinal side effects; elevated liver enzymes reported in <2% of patients; no mention of hepatitis or jaundice).
• Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18-22. [PMC free article: PMC164233] [PubMed: 12842950]

  (Among 397,537 patients who received a prescription for an NSAID [770,000 person years] between 1997 and 2002, 42 developed an acute nonviral hepatitis including 1 of 4232 receiving meloxicam).
• Lacroix I, Lapeyre-Mestre M, Bagheri H, Pathak A, Montastruc JL; Club de Reflexion des cabinets de Groupe de Gastro-Enterologie(CREGG); General Practitioner Networks. Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol 2004; 18: 201-6. [PubMed: 15066135]

  (Case controlled study of patients presenting with suspected drug induced liver injury in a general practice context in Southern France found 88 cases and identified 178 controls; 22 cases vs 16 controls were exposed to NSAIDs; 5 diclofenac, 4 ibuprofen, 4 ketoprofen, 2 niflumic acid, 1 flurbiprofen, and 1 meloxicam, rest to salicylates which was used as frequently in controls; no fatalities).
• Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-98. [PubMed: 15880319]

  (Review of randomized clinical trials of NSAIDS for frequency of adverse events; ALT >3 times ULN occurred in 0.43% of ibuprofen, 0.43% naproxen, 0.42% celecoxib, 1.8% rofecoxib, 3.55% diclofenac, and 0.29% of placebo recipients; among 10,048 patients in five publications on meloxicam, rate was 0.19% and thus less than reported with placebo).
• Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-1101. [PubMed: 16165719]

  (Survey of all cases of drug induced liver injury with fatal outcome from Swedish Adverse Drug Reporting system from 1966-2002; among 103 cases, 3 attributed to naproxen, but none to meloxicam).
• Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006; 20:391-5. [PubMed: 16867024]

  (Analysis of reports of liver injury from NSAIDs from France and Spain from 1982-2001; among more than 29,000 liver adverse event reports, 26 were for meloxicam; no clinical details given).
• Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006; 15: 861-72. [PubMed: 17086563]

  (Survey of NSAID use in UK and USA indicates meloxicam is among the top 10 NSAIDs used).
• Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28: 1123-32. [PubMed: 16982289]

  (Among more than 300,000 spontaneous reports of adverse events due to NSAIDs, 3% being hepatic; the proportion of adverse events that were hepatic was highest for bromfenac [20.7%] and nimesulide [14.4%], but was also elevated for sulindac [9.9%], diclofenac [4.7%], and less so for meloxicam [3.8%]).
• Raber A, Heras J, Costa J, Fortea J, Cobos A. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Management 2007; 3: 225-230. [PMC free article: PMC1936304] [PubMed: 18360631]

  (Summary analysis of spontaneous reports to WHO in first year of meloxicam use suggested liver toxicity was highest with rofecoxib [0.775], intermediate with aceclofenac [0.241], and lowest with meloxicam [0.097 per million drug doses]).
• Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. PubMed Citation18955056 [PMC free article: PMC3654244] [PubMed: 18955056]

  (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, NSAIDs were implicated as a sole agent in 8 cases [4 diclofenac, 2 celecoxib, 1 meloxicam, and 1 oxaprozin] and as one of several agents in 3 cases [1 diclofenac, 1 celecoxib, 1 ibuprofen]).
• Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, et al. A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer 2009; 63: 72-6. [PubMed: 18499296]

  (44 patients with lung cancer given carboplatin and paclitacel with meloxicam; 3 developed elevations in ALT, all were mild and resolved; no details given and difficult to attribute to meloxicam vs cancer chemotherapy).
• Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-61. [PMC free article: PMC2997980] [PubMed: 21128314]

  (Review of estimated frequency of drug induced liver injury due to NSAIDs from large published epidemiological studies; meloxicam is not discussed).
• Martínez-Odriozola P, Gutiérrez-Macías A, Ibarmia-Lahuerta J, Muñóz-Sánchez J. Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig Dis Sci 2010; 55: 1191-2. [PubMed: 19399620]

  (64 year old man developed fatigue followed by jaundice 5 to 6 weeks after starting meloxicam with worsening despite stopping meloxicam [bilirubin 2.9 rising to 8.2 mg/dL, AST 768 to 1591 U/L, Alk P 129 to 155 U/L, ANA positive, high globulins], improving with corticosteroid therapy, but still on treatment 6 months later with persistence of mild enzyme elevations [AST 85 U/L]).
• Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-22. [PubMed: 20486732]

  (Combined analysis of 3 large databases on drug induced liver injury from Spain, Sweden and the US; among the 65 agents linked to at least 5 cases, diclofenac [n=38], ibuprofen [28], naproxen [14], nimesulide [9], and piroxicam [5] are listed, but not meloxicam).
• Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. [PMC free article: PMC3992250] [PubMed: 20949552]

  (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, of which 7 were due to NSAIDs, including 4 attributed to bromfenac, 2 to diclofenac, and 1 to etodolac, but none to meloxicam).
• Lapeyre-Mestre M, Grolleau S, Montastruc JL; Adsociation Française des Centres Régionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 2013; 27: 223-30. [PubMed: 21929527]

  (Analysis of 42,389 spontaneous serious adverse event reports to the French Pharmacovigilance database on 8 NSAIDs between 2002 and 2006; liver adverse events were most frequent with nimesulide [0.15 per million daily doses] compared to diclofenac [0.09], ketoprofen [0.09] piroxicam [0.06], naproxen [0.04], meloxicam [0.03], and tenoxicam [0.03]).
• Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. [PubMed: 23419359]

  (Population based prospective analysis of cases of drug induced liver injury seen over a two year period in Iceland identified 96 cases, 6 of which were due to NSAIDS, all 6 attributed to diclofenac, but none were attributed to meloxicam or other NSAIDs).
• Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9. [PubMed: 24552865]

  (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996-2012 identified 176 cases, the most common class of implicated agents being NSAIDS [n=62, 32%], but specific agents were nimesulide [n=53], piroxicam [5], diclofenac [2], gold salts [1], and naproxen [1]; meloxicam was not listed]).
• Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7. PMID: 25754159 [PMC free article: PMC4446235] [PubMed: 25754159]

  (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 28 were attributed to NSAIDs, 3 of which were attributed to meloxicam all of which were symptomatic and jaundiced but none of which were fatal [Schmeltzer 2016]).
• Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, Russo MW; Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36: 603-9. [PMC free article: PMC5035108] [PubMed: 26601797]

  (Among 1221 cases of drug induced liver injury enrolled in a prospective, US database between 2004 and 2014, 30 cases [2.5%] were attributed to NSAIDs, including 3 to meloxicam, all with a short latency [<1 month], cholestatic or mixed enzyme elevations, moderate severity and ultimately full resolution).
• Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O, Motola D, Moretti U, et al.; DILI-IT Study Group. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol 2016; 82: 238-48. [PMC free article: PMC4917796] [PubMed: 26991794]

  (Among 179 cases of acute liver injury and 1770 controls admitted to 9 Italian hospitals between 2010-2014, NSAIDs that were used more frequently in cases than controls included nimesulide [17% vs 10%: odds ratio 1.88] and ibuprofen [14% vs 10%: odds ratio 1.59], and risk was higher in those taking higher doses; meloxicam was not mentioned).
• Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol 2018; 2018: 5253623. [PMC free article: PMC5820561] [PubMed: 29568654]

  (A systematic review of published randomized controlled trials of NSAIDs for evidence of hepatotoxicity found only 18 studies that fit the stringent criteria including 11 for diclofenac, 5 for naproxen, but none for meloxicam).
• Bergese SD, Melson TI, Candiotti KA, Ayad SS, Mack RJ, McCallum SW, Du W, et al. A phase 3, randomized, placebo-controlled evaluation of the safety of intravenous meloxicam following major surgery. Clin Pharmacol Drug Dev 2019; 8: 1062-72. [PMC free article: PMC6899482] [PubMed: 30786162]

  (Among 721 patients who were treated with once daily intravenous meloxicam [30 mg] or placebo for 1-7 days after undergoing major surgery, adverse event rates were similar in the two groups including ALT elevations [2% vs 3.8%] and those above 3 times ULN [2.0% vs 2.4%], and there were no serious hepatic events).
• Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, et al. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Vietnamese spontaneous adverse drug reaction database: a subgroup approach to disproportionality analysis. J Clin Pharm Ther; 44: 69-77. [PubMed: 30129156]

  (Among 136 cases of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis reported to a Vietnamese national adverse event registry between 2010-2015, the major causes were carbamazepine [n=25], acetaminophen [22], allopurinol [15], cephalosporins [15], HDS [7], SMZ/TMP [6], rifampicin [5], ethambutol [4], streptomycin [4], colchicine [4], valproate [3], and meloxicam [3]).
• Rechberger T, Mack RJ, McCallum SW, Du W, Freyer A. Analgesic efficacy and safety of intravenous meloxicam in subjects with moderate-to-severe pain after open abdominal hysterectomy: a phase 2 randomized clinical trial. Anesth Analg. 2019;128:1309-1318.. [PMC free article: PMC6530966] [PubMed: 31094806]

  (Among 486 women undergoing open elective hysterectomy who were treated on post-operative day 1 with a single infusion of intravenous meloxicam [5, 7.5, 15, 30 or 60 mg], morphine [0.15 mg/kg] or placebo, pain relief was similar with meloxicam and morphine and superior to placebo, there were no treatment related serious adverse events and transient serum enzyme abnormalities arose in 5 [1%] meloxicam vs 2 [0.4%] placebo recipients).
• Sharpe KP, Berkowitz R, Tyndall WA, Boyer D, McCallum SW, Mack RJ, Du W. Safety, tolerability, and effect on opioid use of meloxicam iv following orthopedic surgery. J Pain Res. 2020 Jan 21;13:221-229.. [PMC free article: PMC6982445] [PubMed: 32021411]

  (Among 379 patients undergoing orthopedic surgery treated with intravenous meloxicam or placebo post-operatively for up to 7 days, adverse event rates were similar in the two groups [65% vs 69%] as were “hepatic” events [9.5% vs 7.3%]).
• IV meloxicam (Anjeso) for pain. Med Lett Drugs Ther. 2020;62(1601):100-102.. [PubMed: 32724022]

  (Concise review of the mechanism of action, clinical efficacy, safety, and costs of intravenous meloxicam for pain shortly after its approval for use in the United States, mentions adverse effects of constipation, GGT elevations, and anemia but overall rates of adverse events were similar to those in placebo groups; states hepatotoxicity occurs rarely with NSAID therapy).
• Silinsky JD, Marcet JE, Anupindi VR, Karkare SU, Shah DR, Mack RJ, McCallum SW, et al. Preoperative intravenous meloxicam for moderate-to-severe pain in the immediate post-operative period: a Phase IIIb randomized clinical trial in 55 patients undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis. Pain Manag. 2021;11:9-21.. [PubMed: 33094682]

  (Among 55 adults undergoing colorectal surgery who were treated for moderate-to-severe pain postoperatively with either intravenous meloxicam or placebo, both pain and opiate use was less with meloxicam, adverse event rates were similar in the two groups, and there were no differences in clinical laboratory findings).
• Berkowitz RD, Mack RJ, McCallum SW. Meloxicam for intravenous use: review of its clinical efficacy and safety for management of postoperative pain. Pain Manag. 2021;11:249-258.. [PubMed: 33291975]

  (In multiple phase II and III controlled trials of intravenous meloxicam given pre- and post-operatively of various forms of surgery, meloxicam was consistently more effective than placebo for pain relief and similar to intravenous ketorolac, while adverse event rates, including ALT elevations [2% vs 4%] and “hepatic events” [6.5% vs 8.2%] were similar with meloxicam as with placebo or an active control).
• Hu F, Wu G, Zhao Q, Wu J. Evaluation of analgesic effect, joint function recovery and safety of meloxicam in knee osteoarthritis patients who receive total knee arthroplasty: a randomized, controlled, double-blind study. Medicine (Baltimore). 2021;100:e26873.. [PMC free article: PMC8415958] [PubMed: 34477120]

  (Among 128 Chinese adults undergoing total knee arthroplasty for osteoarthritis who were treated with either oral meloxicam or placebo 4 to 72 hours post-operatively, pain relief was better with meloxicam and rates of adverse events [nausea, constipation, dizziness) were similar between the two groups; no mention of ALT levels).
• Yuan H, Curran JG, Keith SW, Hopkins MM, Silberstein SD. Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study. Headache. 2021;61:1432-1440.. [PubMed: 34601736]

  (Among 74 patients with acute migraine treated with either intravenous ibuprofen or placebo within 2 to 72 hours of onset, pain relief was attained within 2 hours in 74% vs 48%, and adverse event rates were similar [17% vs 14%], and no serious adverse events occurred).
• Bupivacaine/meloxicam (Zynrelef) for postsurgical pain. Med Lett Drugs Ther. 2022;64(1642):13-15.. [PubMed: 35134044]

  (Concise review of the mechanism of action, clinical efficacy, safety, and costs of the combination of bupivacaine and meloxicam as an extended release solution for single dose intraoperative parenteral instillation, mentions that the combination provided better post-operative pain relief and that side effects were largely constipation, nausea, and headache but also mentions that systemic NSAIDs can cause ALT and AST elevations).
• Haffar A, Fillingham YA, Breckenridge L, Gursay D, Lonner JH. Meloxicam versus celecoxib for postoperative analgesia after total knee arthroplasty: safety, efficacy and cost. J Am Acad Orthop Surg Glob Res Rev. 2022;6:e22.00032. PMID: 35389917. [PMC free article: PMC8989775] [PubMed: 35389917]

  (In a retrospective analysis of 4994 patients who underwent total knee arthroplasty between 2015 and 2020 treated post-operatively with either meloxicam [7.5 or 5 mg] or celecoxib once daily, there were no differences in rates of complications including gastrointestinal bleeding, thromboses, wound complications, and renal injury; no mention of ALT levels or hepatotoxicity).
• Nonopioid drugs for pain. Med Lett Drugs Ther. 2022;64(1645):33-40.. [PubMed: 35231019]

  (Concise review of the nonopioid drugs for pain mentions that NSAIDs are considered to be more effective than acetaminophen for mild to moderate pain and that they can cause small increases in serum aminotransferase levels but that serious hepatotoxicity is rare, occurring most frequently with diclofenac, while cholestatic hepatitis has been reported with use of celecoxib).
• Bonkovsky HL, Ghabril M, Nicoletti P, Dellinger A, Fontana RJ, Barnhart H, Gu J, et al; US DILIN Investigators. Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-update with genetic correlations. Liver Int. 2024;44:1409-1421.. [PMC free article: PMC12009671] [PubMed: 38451034]

  (Among 55 cases of drug induced liver injury attributed to NSAIDs enrolled in a U.S. database between 2004 and 2022, 4 were attributed to meloxicam including 3 women and 1 man, median age 65.7 years, latency 23 days, initial bilirubin 5.9 mg/dL, ALT 241 U/L, and Alk P 366 U/L).
• Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, Park LS, et al. Severe acute liver injury after hepatotoxic medication initiation in real-world data. JAMA Intern Med. 2024;184:943-952.. [PMC free article: PMC11197444] [PubMed: 38913369]

  (Analysis of the US Veterans Administration electronic health records between 1999 and 2021 identified 1739 hospitalizations for acute liver injury suspected to be attributed to prescribed medications, at rates for NSAIDs of 1:7,700 for sulindac, 1:8,300 for indomethacin, 1:9,100 for naproxen, 1:11,000 for ibuprofen, 1:12,500 for diclofenac, and 1:14,300 for celecoxib; meloxicam was not mentioned).
• Chen VL, Rockey DC, Bjornsson ES, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network Investigators. Incidence of idiosyncratic drug-induced liver injury caused by prescription drugs. Drug Saf. 2025;48:151-160.. [PMC free article: PMC11785493] [PubMed: 39317916]

  (Analysis of 1284 cases of drug-induced liver injury enrolled in a U.S. prospective study, identified 23 cases due to diclofenac for an estimated incidence of 1 per 4,800 new persons treated each year, while other NSAIDs had lower numbers and estimated rates, including celecoxib [4, 1:25,000] and meloxicam [n=3, 1:87,000], incidence rates for ibuprofen and naproxen could not be estimated because of lack of data on over-the-counter use).
• Bessone F, Hernandez N, Medina-Caliz I, García-Cortés M, Schinoni MI, Mendizabal M, Chiodi D, et al. Drug-induced liver injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network. Clin Gastroenterol Hepatol. 2025;23:89-102.. [PubMed: 38992407]

  (Among 458 cases of idiosyncratic drug-induced liver injury enrolled in a prospective Latin American database over a 10 year period, 49 were attributed to NSAIDs, including 19 [4.1%] to diclofenac, 14 [3.0%] to nimesulide and 11 [2.4%] to ibuprofen, and 1 case each to celecoxib, ketoprofen, ketorolac, meloxicam, and piroxicam [personal communication]).
• A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. Med Lett Drugs Ther. 2025;67(1727):68-70. PMID:.40261316 [PubMed: 40261316]

  (Concise review of the mechanism of action, clinical efficacy, safety, and costs of the combination of meloxicam and rizatriptan as therapy for migraine shortly after its approval for use in the United States does not mention ALT elevations or hepatotoxicity).